Editorial: Extracellular vesicles: emerging roles in the aged and neurodegenerative brain
Foteini Vasilopoulou,Jennifer Pocock,Gal Bitan,Dirk M. Hermann
DOI: https://doi.org/10.3389/fncel.2024.1522499
2024-12-10
Frontiers in Cellular Neuroscience
Abstract:Over the past few decades, central nervous system (CNS) and peripheral nervous system (PNS) secreted nanosized extracellular vesicles (EVs) have emerged as promising biological platforms for advancing our understanding of intercellular communication, molecular transfer, and mechanisms underlying neurodegenerative and other CNS or PNS diseases (Mallach et al., 2021b, 2021a; Li et al., 2022; Hermann et al., 2024). EVs are released by virtually all cells in the CNS and PNS and carry an heterogeneous cargo of proteins, DNAs, RNAs, metabolites and lipids, that varies reflecting the state and origin of their parent cells. Once released into the extracellular space, EVs modulate cellular responses in the recipient cells to promote protective effects yet sometimes, inadvertently propagate toxic signals in a context-dependent manner. Importantly, their ability to deliver functional cargo, cross biological barriers, and reflect the state of their parent cells makes them promising candidates for therapeutics, biomarkers, and drug delivery systems (Bravo-Miana et al., 2024; Hermann et al., 2024). In this expanding field, researchers are increasing efforts to address scientific gaps related to the mechanisms regulating cargo loading, secretion and uptake, as well as the intra- and intercellular pathways triggered by EVs in disease, with the aim of enhancing their potential for clinical application. This research topic features two original studies and two reviews that provide new insights into the mechanisms by which EVs contribute to nervous system disease progression, opening avenues for therapeutic strategies and diagnostic advancements in neurological disorders. The diseased CNS is often characterised by the presence of neuroinflammation, a process orchestrated by glial cells, including astrocytes and microglia, that relies on dynamic glia-glia or glia-neuron crosstalk. Such communication among cells occurs either through direct cell-cell contact or via cellular secretome products (Bernaus et al., 2020; Matejuk and Ransohoff, 2020; Middeldorp et al., 2023). Increasing evidence indicates that glia-released EVs can transmit inflammatory signals among CNS cells either fuelling the vicious cycle of inflammation (Gupta and Pulliam, 2014) or promoting inflammatory resolution (Markoutsa et al., 2022) through molecular mechanisms that remain an active area of research. Memo et al. (2024) explored the role of a subclass of CNS-released EVs, identified as small EVs (sEVs), in regulating CNS local tissue reactivity to inflammatory stimulus and inflammation spreading, with implications for neurodegenerative diseases, or any disease characterized by neuroinflammation. Using spinal cord organotypic cultures to mimic CNS resting and lipopolysaccharide (LPS) induced reactive states the authors exposed naïve (so far healthy) slices to sEVs released by resting or reactive spinal resident cells. They show that reactive sEVs induce the secretion of proinflammatory cytokines and chemokines, alter microglia morphology and trigger aberrant astrocyte calcium dynamics in naïve slices. Importantly, their results led to the proposal that the recruitment of naïve astrocytes by inflammatory sEVs is associated with increased astrocytic hemichannel permeability. Further supporting this, they observe that by specifically blocking connexin43 hemichannels expressed in sEVs, the inflammatory response in naïve slices is prevented; however, the underlying mechanisms need to be elucidated. These findings not only build upon the foundation laid by previous studies on EVs' critical role in propagating neuroinflammation, but also introduce a specific interaction between EV hemichannels and astrocyte membrane that has the potential to shift the understanding of the molecular mechanisms whereby sEVs mediate their effects to recipient cells. As mentioned earlier, a key aspect in EV biology and potential for clinical application as biomarkers of CNS pathologies is their ability to mirror the state and content of the parental cells. Therefore, to fully unlock their potential, it is essential to use well-characterised and reliable cellular models that closely recapitulate human complexity. In this regard, modelling human CNS diseases in cell culture remains a challenging yet active area of research. Progress in this field should be regularly considered by researchers in the EV field to ensure that preclinical findings are translatable to clinical practice. White et al. (2024) address concerns arising from the prolonged use of serum when using cultured human astrocyte, and the reliability of the resulting astrocyte-derived EVs as per their cargo and state. The authors compare human astrocytic cultures in serum-containing and serum-free conditions and identify differences in morphology, astrocytic marker expression, proinflammatory cytokine release, transcriptome and proteome of the cells, suggesting differences i -Abstract Truncated-
neurosciences